Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search


Chief Commercial Officer At Helius Announced

Mark Morrison has been appointed Chief Commercial Officer (CCO) at Helius Therapeutics - New Zealand’s largest licenced medicinal cannabis company.

Mark Morrison

For six months prior to the appointment, he was a consultant at Helius where he developed the company’s commercial strategy. The announcement of CCO completes the executive leadership team at the headquarters of Helius in Auckland’s East Tamaki.

With significant experience in Australia, United States and New Zealand, Mr Morrison has worked in the pharmaceutical, animal health, and FMCG industries for over 25 years. He has held senior global marketing, strategic planning, new product and business development positions, and has consulted in the medicinal cannabis sector since 2018.

He has an MBA from Australia’s Macquarie Graduate School of Management, and a Bachelor of Science (Hons) from the University of Canterbury.

The Chief Executive says the Helius leadership team has highly complementary skill sets and a diversity of thinking to get the job done, with a large focus on innovation, scientific and technical prowess.

“Announcing our CCO completes our internationally-experienced team. This appointment also reinforces that after a long journey, we’re now at the business end. We’re looking forward to serving Kiwi patients, with a big eye on establishing key export markets,” says Carmen Doran, Chief Executive of Helius Therapeutics.

The 100% New Zealand-owned private biotechnology company has brought together a multi-disciplinary executive team. It has deep experience across pharmaceutical operations, cannabinoid research and development, and quality systems.

“Mark brings a broad range of experiences which Helius is already benefiting from. He understands the complex challenges of medicines manufacturing and getting highly regulated products into market. His considerable time in animal healthcare, here and the US, is also invaluable for our sister company Hale,” she says.

Helius - Auckland Building

Part-owned by Helius, Hale Animal Health has launched its own scientifically formulated range of pet supplements crafted from premium ingredients. Hale is also leading the way in developing some of the world’s first cannabinoid medicines for companion animals.

“CBD is highly effective for treating the likes of pain and inflammation in humans, and it’s no different for animals. They have an endogenous cannabinoid system just like us, meaning cannabis therapeutics work in a similar way for pets,” says Leila de Koster, Managing Director of Hale Animal Health.

Mr Morrison is excited about seeing the medicinal cannabis sector in New Zealand transitioning from an aspirational space to one of delivery.

“A key part of our commercial strategy is rolling out some comprehensive educational support for both patients and prescribers. In the coming months, we’ll be launching a number of initiatives to ensure everyone has the support and access to trusted and leading information. It’s an incredibly exciting time to be part of Helius and in fact New Zealand’s newest sector,” says Mr Morrison.

Having raised $48m in capital since 2018, Helius completed its state-of-the-art, integrated medicines manufacturing facility late last year. At 8,800sqm, it enables integrated cultivation, analytics, research, manufacturing, logistics, management, and distribution all under one secure roof.

Ms Doran believes New Zealand is poised to become an innovation hub for medicinal cannabis, with the sector representing a substantial social and economic opportunity for the country. Helius will be a key driver in the sector’s success and the first local company to undertake medicinal cannabis clinical trials.

“Helius is all about establishing and earning its position as a world leader in scientific research and development. Most importantly, our genuine care for patients and their quality of life is at the heart of everything we do. Helius has the team to deliver - and deliver big,” says Ms Doran.

The executive leadership team at Helius is Carmen Doran (Chief Executive Officer); Mary Alice Simon (Chief Operations Officer); Dr Jim Polston (Chief Science Officer); Bruce Wallace (Chief Quality Officer); Mark Woods (Chief Financial Officer); and Mark Morrison (Chief Commercial Officer).

Helius Therapeutics is the foundation sponsor of MedCan Summit 2021, which will take place on 12 and 13 October in Auckland.


About Helius

Helius is a focused on medicinal cannabis research, innovation, manufacturing and commercialisation. It is the country’s largest licenced producer and the first medicinal cannabis cultivator to be certified as New Zealand Grown through Buy NZ Made Campaign. The company operates a state-of-the-art, integrated facility in Auckland with indoor controlled growing systems, extraction site, an advanced cannabinoid research laboratory and manufacturing. Following changes to New Zealand’s regulatory environment, Helius is poised to set the standard for effective and accessible medicinal cannabis products in New Zealand and beyond.

© Scoop Media

Business Headlines | Sci-Tech Headlines


Maritime Union: Deepening Supply Chain Crisis Requires Action

Maritime Union of New Zealand National Secretary Craig Harrison says the global COVID-19 pandemic exposed pre-existing weaknesses in our logistics sector, and created enormous problems... More>>

Air New Zealand: Employees Recognised With $1,000 Share Award

The efforts Air New Zealand employees made during one of the airline’s toughest years will be recognised via an award of $1,000 worth of company shares to all permanent employees... More>>

Consumer NZ: Bank Complaints On The Rise, Survey Shows

Nearly one in five Kiwis had a problem with their bank in the past year, Consumer NZ’s latest satisfaction survey finds. Consumer NZ chief executive Jon Duffy said the number of bank customers reporting problems had jumped to 18%, up from 11% in 2020... More>>

Mercury: Enters Into Binding Agreements To Acquire Trustpower’s Retail Business

Mercury NZ Limited (Mercury) has announced that it has entered into binding agreements with Trustpower Limited (Trustpower, NZX:TPW) to acquire Trustpower’s retail business for NZ$441 million... More>>


ASB: New Zealanders Missing Out On Hundreds Of Millions In KiwiSaver Government Contributions

New Zealanders have just over a week to ensure they’re eligible for the maximum annual government KiwiSaver contribution... More>>

Stats NZ: GDP Climbs 1.6 Percent In March 2021 Quarter Following December Dip

Gross domestic product (GDP) rose by 1.6 percent in the March 2021 quarter, following a 1.0 percent fall in the December 2020 quarter, Stats NZ said today. "After an easing of economic activity in the December quarter, we’ve seen broad-based growth in the first quarter of 2021... More>>